Introduction
patients was observed between radiotherapy alone and radiotherapy combined with CHOP chemotherapy (Wang et al., 2007) . Others have argued that both recent response rate and long-term survival rate of combined therapy are superior to those of radiotherapy (Lee et al., 2008; Zhang et al., 2013) . To further clarify the proper treatment for these patients so as to achieve long-term remission rate and survival rate, we employed Cochrane systematic reviews to assess related randomized controlled trial (RCT) in China and provide reference for clinical application.
Materials and Methods

Inclusion and exclusion criteria
Design type: Design type was included in domestic RCT and quasi-RTC regardless of application of blind method and loss of follow-up. Language was Chinese.
Subjects: Subjects were patients diagnosed with stage IE~IIE ENK/TCL.
Intervention measures: Different treatments were compared: radiotherapy group, chemotherapy group, combined therapy group (including radio-chemotherapy group and chemo-radiotherapy group), radio-chemotherapy group (radiotherapy followed by chemotherapy) and chemo-radiotherapy group (chemotherapy followed by radiotherapy); the clinical trials constituted by multiple sets of intervention measures only provided the data of related intervention measures.
Outcome indicators: Judgment was in accordance with Response Evaluation Criteria in Solid Tumors or WHO criteria (Kinney Mc et al., 1999; Kamiyama T et al., 2009) . Outcome indicators included complete response rate (CRR) and 1, 3, 5-year survival rate. CR was defined as the tumor completely disappeared after treatment; no tumor was observed in physical examination and imaging examination for more than one month. Survival rate was calculated from the first day of treatment to the date of death caused by any reason or the last day of follow-up.
Exclusion criteria: Descriptive research, research without control group and research with duplicate publication was excluded.
Retrieval strategy
Computer-based retrieval was performed in PubMed, CNKI (1989 CNKI ( .1-2013 , CBM (1989 CBM ( .1-2012 , VIP (1989 VIP ( .1-2013 .2) and WanFang Data (1989 Data ( .1-2013 .2); all references incorporated into literature were manually retrieved. Extranodal natural killer/T cell lymphoma and radiotherapy, chemotherapy were used as search terms.
Data extraction
Two evaluators independently screened the literature according to inclusion and exclusion criteria, extracted data and crosschecked. The disagreement in case was solved through discussion or ruled by a third party. Extracted data covered first author, published year, specific symptoms, intervention measures, course of treatment and clinical efficacy, etc.
Quality evaluation of included studies
Criteria for assessing risk of bias in Cochrane Handbook for Systematic Reviews (Version 5.1.0) was employed to evaluate methodological quality of included studies.
Statistical study
Statistical analysis of data was performed with RevMan 5.0 software provided by Cochrane collaboration. Effect size of efficacy utilized interval estimation and hypothesis test. Enumeration data was presented in odds ratio (OR) and its 95%CI was reported. Hypothesis test employed Z test and was described with Z values and P values; P≤0.05 between two groups was considered significant; the results of interval estimation and hypothesis test were shown in the forest plot. Heterogeneity test of included study was firstly carried out and P<0.10 (due to low power of homogeneity test, significant level was always defined as α=0.10) was considered statistically significant. At the same time I
2 was used for quantitative analysis of heterogeneity: I 2 <25% was low heterogeneity, 25%≤I 2 ≤50% was moderate heterogeneity, I
2 >50% was high heterogeneity. If the research had no statistical heterogeneity (P≥0.10, I 2 ≤50%), the fixed effect model was selected for Meta analysis; if the research had statistical heterogeneity (P<0.10, I 2 >50%), random effect model could be used for Meta analysis.
Results
Retrieved result and characteristics of included studies
According to the retrieval strategy, a total of 442 related references were checked, among which 53 were preliminary screened after reading the title, abstract and excluding repetitive non-clinical studies and literature that was not related to treatments. Eventually 11 RCT were selected after going through the full articles, which included 871 patients with stage IE~IIE ENK/TCL who were divided into radiotherapy group, chemotherapy group, radio-chemotherapy group and chemo-radiotherapy group . The characteristics of included studies were shown in Table 1 . There were no differences in gender, age, clinical stage between test and control groups (Table 1) .
Quality evaluation of included studies
All included studies reported general conditions of patients with complete result data, but did not described random, blind method and loss of follow-up in details, as well as allocation concealment. Therefore, the overall evaluation was relatively low.
Efficacy and safety evaluation
Efficacy evaluation: Efficacy evaluation of 11 RCT was carried out from the following four aspects: first radiotherapy VS first chemotherapy; combined therapy VS radiotherapy; combined therapy VS chemotherapy; radio-chemotherapy VS chemo-radiotherapy. Evaluation index was CRR.
Among 11 RCT, four of them (Jin Jing et al., 2006; Yao Bo et al., 2006; Wu Fueraikemu et al., 2008; Nie Dahong et al., 2010; Kang Gongli et al., 2012) compared the efficacy between first radiotherapy and first chemotherapy Figure 1 .
Among 11 RCT, four of them (Jin et al., 2006; Lin et al., 2009; Zhao et al., 2011; Zheng et al., 2012) compared the efficacy between combined therapy and radiotherapy in 320 patients, including 215 cases of combined therapy and 217 cases of radiotherapy, and the results showed that 170 and 76 patients had complete response with CRR of 79.07% and 72.38% in combined therapy and radiotherapy groups, respectively. Statistical heterogeneity was found among studies (P=0.06, I 2 =55%), thus random effect model was used for Meta analysis. Combined analysis results suggested that CRR had no statistical difference [OR=1.30, 95%CI (0.47, 3.58), P=0.61], i.e. combined therapy and radiotherapy groups had similar CRR, shown in Figure 2 .
Among 11 RCT, three of them (Jin et al., 2006; Yang et al., 2009; Zhao et al., 2011) Safety evaluation: Among 11 RCT, two of them (Yang Yong et al., 2009; Nie Dahong et al., 2010) reported untoward effects, which were mainly manifested as gastrointestinal symptoms, such as nausea and vomiting, myelosuppression, cutaneous reaction, oral mucosa reaction and throat reaction, or even massive hemorrhage of gastrointestinal tract and severe bone marrow suppression, etc. Chemo-radiotherapy group had highest incidence of side effects (21%), while radio-chemotherapy group had highest mortality (50%) (Lee et al., 2013) , but Meta analysis was not conducted due to small number of reported cases.
Survival rate evaluation
One, three, five-year survival rates of included studies were assessed from the following three aspects: combined therapy VS radiotherapy; combined therapy VS chemotherapy; radio-chemotherapy VS chemoradiotherapy.
Comparison of survival rate between combined therapy and radiotherapy groups: Among 11 RCT, two of them (Wang Hu et al., 2005; Zheng Naiying et al., 2012) compared three-year survival rate and six of them (Wang Figure 3 .
Comparison of survival rate between combined therapy and chemotherapy groups: Among 11 RCT, two of them (Wang et al., 2005; Nie et al., 2010) Figure 4 .
Comparison of survival rate between radiochemotherapy and chemo-radiotherapy: Among 11 RCT, two of them (Wang Hu et al., 2005; Nie Dahong et al., 2010 ) compared one, three-year survival rates and five of them (Wang Hu et al., 2005; Yao Bo et al., 2006; Ma Huihui et al., 2007; Wu Fueraikemu et al., 2008; Nie Dahong et al., 2010) reported five-year survival rate in 516 patients, including 173 cases of radio-chemotherapy and 343 cases of chemo-radiotherapy, and the results showed that no statistical differences in one, three, five-year survival rates [OR=0.98, 95%CI (0.33, 2.94 Figure 5 .
Discussion
ENK/TCL often occurs in East Asia and Latin America, but is relatively rare in Europe and the United States. Its morbidity is consistent with the rate of EB virus infection in the geographic distribution. Research in recent years has demonstrated that CD3 and CD56 present in the cytoplasm of theses tumor cells, which simulteneously express cytotoxic granule proteins, such as TIA-1 and EB virus antigen (Steven H et al., 2008; Au WY et al., 2009; Gill H et al., 2010; Gualco G et al., 2011; Shaoying Li et al., 2013) . ENK/TCL has poor prognosis and is influenced by many factors, including age, LDH value, the titer of Epstein-Barr virus (EBV) DNA, absolute lymphocyte count and the positive expression of CD30 (Au et al., 2004; Lee et al., 2005; Hong et al., 2012; Li et al., 2013) etc. The new study also shows that fasting blood glucose level in patients also affects their long-term survival (Cai et al., 2013) .
So far, people at home and abroad have an agreement on the treatment for early ENK/TCL: radiotherapy alone is superior to chemotherapy alone (Kohrt et al., 2009; Kim et al., 2010) , but radiotherapy alone likely causes disease recurrence even it easily relieves the patients . It is pity that there is no systemic Meta analysis either in China or other foreign countries regarding whether combination of chemotherapy and radiotherapy can improve CRR and long-term survival of these patients and increase the incidence of untoward effects. We compared the efficacy, safety and survival rate of patients with early ENK/TCL who underwent radiotherapy, chemotherapy and combine therapy, and the results displayed that first radiotherapy had higher CRR than first chemotherapy (P<0.00001), but no statistical difference in CRR was observed between combined therapy and radiotherapy alone (P=0.61); while combined therapy group had higher long-term survival rate than radiotherapy group (P=0.002). These results indicated that as for shortterm efficacy, chemotherapy had significance for patients with early ENK/TCL to achieve complete response; combined therapy extended long-term survival of patients although it could facilitate more patients to achieve complete response than radiotherapy did. In addition, the order of chemotherapy and radiotherapy in combined therapy had no effects on CRR and long-term survival rate of patients. At the same time, the side effects in combined therapy group were more than those of other groups, which were manifested as gastrointestinal symptoms and myelosuppression. Therefore, comprehensive and detailed evaluation of patients should be done before the therapy, so as to apply individualized treatment and benefit the patients. With respect to the scheme of combine therapy, large number of studies Gill et al., 2010; Zheng et al., 2012; Kang et al., 2012; ect) has reported that the radioactivity of 50Gy and1.8-2Gy/time are optimal for the patients, who poorly response to CHOP chemotherapy because these patients are not sensitive to anthracycline-based chemotherapy scheme duo to multidrug resistance induced by high expression level of P-glycoprotein . Whether etoposide or L-asparaginase-based chemotherapy that can overcome multidrug resistance mediated by P-glycoprotein should be applied still requires further research (Yong et al., 2009; .
Included studies in our research have disadvantages as follows: (1) the overall methodological quality of 11 RCT was relatively low with high possibility of selection bias, performance bias and measurement bias; (2) there were some differences in the course of therapy and specific therapeutic measures, thus the studies had certain clinical heterogeneity, which might affect comprehensive analysis results.
In conclusion, the treatment of patients with early ENK/ TCL in China was mainly radiotherapy. The combination of radiotherapy and chemotherapy had its advantages in further enhancing the long-term survival rate of patients, but considering that combined therapy likely brought more side effects, individualized treatment should be applied. At present, the conclusive Meta analysis has provided references for the clinical treatment of this disease, but further randomized, double-blind controlled trials with rigorous design, reliable methods and high quality are required in order to comprehensively, objectively and correctly evaluate the efficacy, safety and long-term survival rate of the treatment for early ENK/TCL.
